TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer

Abstract

Colorectal cancer (CRC) is one of the most common neoplasms worldwide. However, the mechanisms underlying its development are still poorly understood. Thyroid hormone Receptor Interactor 13 (TRIP13) is a key mitosis regulator, and recent evidence has shown that it is an oncogene. Here, we report that TRIP13, which is overexpressed in CRC, is correlated with the CEA (carcino-embryonic antigen), CA19-9 (carbohydrate antigen 19-9) and pTNM (pathologic primary tumor, lymph nodes, distant metastasis) classification. Multivariate analyses showed that TRIP13 might serve as an independent prognostic marker of CRC. We also found that TRIP13 promoted CRC cell proliferation, invasion and migration in vitro and subcutaneous tumor formation in vivo. Furthermore, the potential mechanism underlying these effects involves the interaction of TRIP13 with a 14-3-3 protein, YWHAZ, which mediates G2-M transition and epithelial-mesenchymal transition (EMT). Together, these findings suggest that TRIP13 may be a potential biomarker and therapeutic target for CRC.

Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways

“…And these annotations were mainly related to the processes of cell proliferation and differentiation. Previous studies have demonstrated that TRIP13 promoted cell proliferation and invasion via interacting with YWHAQ and YWHAZ in CRC [10]. And TRIP13 mutations predispose to chromosome missegregation and tumorigenesis [8].…”

“…plays an oncogenic role in multiple human cancers and usually associated with poor survival [9,10,22,23]. Here, we determined to explore the role of TRIP13 in BC.…”

“…Accumulating evidence has shown that TRIP13 protein levels are operational in several human cancers, including ovarian cancer, colorectal cancer, prostate cancer, and Wilms' tumor, etc [7][8][9][10].…”

“…Aberrant expression of TRIP13 might be related to the occurrence and development of tumor, and the up-regulation of TRIP13 can promote the cell proliferation, migration and increase the resistance to chemotherapeutic drugs [9][10][11]. However, the function of TRIP13 in BC has not yet been elucidated.…”

e-MutPath: Computational modelling reveals the functional landscape of genetic mutations rewiring interactome networks

“…We found that the majority of these interactions involved genes that had been demonstrated to play critical roles in cancer, such as TRIP13, MDFI, SPRY2 and MEOX2. Particularly, TRIP13 was found to promote cell proliferation, invasion and migration in cancer (34). In addition, MEOX2 was identified as a target gene of the TGF-beta/Smad pathway and was known to regulate cell proliferation (35).…”